Doctors may be able to use six energy-storing substances known as lipids to diagnose and track the progression of idiopathic pulmonary fibrosis, a Chinese study reports. The research, “Identification of the lipid biomarkers from plasma in idiopathic pulmonary fibrosis by Lipidomics,” appeared in the journal BMC Pulmonary…
News
A real-world study in Britain confirms that Ofev (nintedanib) is a safe and effective treatment for idiopathic pulmonary fibrosis, or IPF. The research, “Early clinical experiences with nintedanib in three UK tertiary interstitial lung disease centres,” was published in the journal Clinical and Translational…
British Regulators Pave Way for Pulmonary Fibrosis Patients to Gain Early Access to Prometic Therapy
British regulators have paved the way for people with severe cases of pulmonary fibrosis to gain access to Prometic Life Sciences’ tissue-scarring therapy PBI-4050 before it is approved. The step the regulators took was to designate PBI-4050 a Promising Innovative Medicine for idiopathic pulmonary fibrosis. The next step would be…
Researchers have found another piece in the molecular puzzle of changes leading to pulmonary fibrosis — a cell signaling factor. It offers scientists a new target for developing lung-scarring treatments. Lung damage leads to the production of a protein that attracts immune cells to the area. Without this signaling, mice…
A factor called Krüpple-like-factor 4, or KLF4, treated lung fibrosis in a mouse model of idiopathic pulmonary fibrosis (IPF) by preventing epithelial cells of the lung from moving into a fibrosis-promoting state, researchers in China report, suggesting its potential as an IPF therapy. The study “Krüpple-like-factor 4 Attenuates Lung…
Thyroid hormone, delivered through aerosol inhalation, helped to resolve lung scarring in a mouse model of idiopathic pulmonary fibrosis (IPF), according to research published in the journal Nature Medicine. The study provides evidence that lung fibrosis is a disease caused — at least partly — by abnormalities in metabolic processes…
An anti-inflammatory agent known as ulinastatin decreases pulmonary fibrosis, and at high doses may protect against lung tissue scarring, a study in rats showed. The research, “Therapeutic effect of ulinastatin on pulmonary fibrosis via downregulation of TGF‑β1, TNF‑α and NF‑κB,” was published in the journal Molecular Medicine Reports.
Veracyte has published new data confirming the analytical validity of its Envisia Genomic Classifier to help diagnose idiopathic pulmonary fibrosis (IPF). Its study, “Analytical performance of Envisia: a genomic classifier for usual interstitial pneumonia,” appeared in the journal BMC Pulmonary Medicine. The 190-gene Envisia Genomic Classifier helps physicians distinguish between IPF and…
In memory of his father, who lived many years with pulmonary fibrosis (PF), Chicago Bears’ Jordan Howard will wear luminous blue-and-green cleats to support the Pulmonary Fibrosis Foundation (PFF) when he takes to the field Sunday, Dec. 3. The PFF is chosen by Howard for the second year in…
A team of researchers discovered that a protein called RAGE can fix damage inflicted to DNA molecules, and also repair lung scarring in mice. The study reporting the findings, “Homeostatic nuclear RAGE-ATM interaction is essential for efficient DNA repair,” was published in the journal Nucleic Acids Research.
Your PF Community
Recommended Posts
- Pulmonary fibrosis pushed my husband to pivot in his career
- Protein linked to mechanical stress drives pulmonary fibrosis: Study
- I’m living proof of the profound impact of organ donation
- From diagnosis to treatment: What life with PF is like, part 2
- New generic of Ofev for IPF approved by FDA, slated for ‘immediate’ launch
